

# A B C N E W S L E T T E R

### URRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2022 #22

#### June 17, 2022

#### Donor-Recipient Gender Associated with Transfusion Outcomes?

Two contrasting studies on the possible link between donor-recipient gender and its impact on transfusion outcomes have been published in <u>Blood Advances</u> and <u>JAMA</u> <u>Internal Medicine</u>. Investigators in the *Blood Advances* study explored the "the associations between donor-recipient sex and posttransfusion mortality and morbidity in critically ill patients who received red blood cell (RBC) transfusions from either male-only donors or from female-only donors (unisex-transfusion cases). Survival analysis was used to compare four groups: female-to-female; female-to-male; male-to-female; and male-to-male transfusion." Their research included "403 patients who received RBC transfusions from female donors (female-to-female), 106 male patients received RBC transfusions from female donors (female-to-male), 90 female patients received RBC transfusions from male donors (male-to-female), and 130 male patients received RBC transfusions from male donors (male-to-male)."

The study found that "[c]ritically ill male recipients of female blood had a higher risk of dying compared with female recipients of female blood. In previous studies, both receipt of female blood as well as donor-recipient sex-mismatched transfusions were found to be associated with mortality. The current study showed that intensive care unit (ICU) mortality was higher in male patients than in female patients, as has been found previously. It has been shown that male ICU patients require higher intensity ICU treatment than female patients. The present study adds to these findings, showing that transfusing blood from female donors to male recipients is the only form of sex-mismatched transfusion that is significantly associated with mortality. The findings of the current study are contrary to other studies suggesting that female recipients of male blood have an increased risk of in-hospital mortality and studies that do not suggest an association between donor sex and patient survival. The authors concluded that their "study shows significant associations between male patients who received RBCs from female donors and ICU mortality, which may in part be due to acute respiratory distress syndrome (ARDS), although other, as yet undetermined, factors are likely to be present. The mechanism of the association of donor-recipient sex and transfusion-related outcomes requires further study."

The researchers in *JAMA Internal Medicine* "emulated a nationwide randomized clinical trial to study the effect of donor sex and parity on mortality of patients undergoing transfusion of RBCs…From a total of 485,327 red blood cell recipients,

#### INSIDE:

WORD IN WASHINGTON
RESEARCH IN BRIEF4
BRIEFLY NOTED4
ABC Participates in Inaugural Patients' International Blood Alliance Meeting5
Webinar Recording and Slides Available: U.S Wide Red Blood Cell Antibody Exchange Project
Registration Opens for MD Workshop and Summer Summit
MEMBER NEWS6
COMPANY NEWS6
CALENDAR7
EQUIPMENT AVAILABLE:
POSITIONS8



#### Donor-recipient gender and the association with transfusion outcomes (continued from page 1)

**ABC** Newsletter

368,778 patients without a history of RBC transfusions were identified." The investigators discovered that "[t]here was statistically significant difference in overall survival at two years between female and male donor strategies (survival difference, -0.1 percent; 95 percent CI, -1.3 percent to 1.1 percent...At two years, there were no statistically significant differences in overall survival comparing parous female donors (survival difference, 0.3 percent; 95 percent CI, -0.6 percent to 1.2 percent) and nonparous female donors (survival difference, 0.1 percent; 95 percent CI, -3.8 percent to 3.2 percent) with male donor strategy...[W]e demonstrated that red blood cell transfusions from female donors incurred a higher risk for additional transfusions owing to lower donor hemoglobin counts in female donors." The authors concluded that in their, "nationwide cohort study involving a natural experiment, patients undergoing transfusion with blood from female or parous donors did not have a higher two-year mortality compared with recipients of blood from male donors. Red blood cell units from female donors contained less hemoglobin compared with units from male donors, which is a hitherto unrecognized source of confounding that cannot be accounted for using standard regression models and, to our knowledge, has not been considered in previous studies." Limitations of this study included that the authors did not "assess extreme cases or exposures that did not occur in a real-world setting and truncated exposure at the 99th percentile of the number of transfusions from the same donor sex or parity... We did not evaluate other blood products and did not differentiate between red blood cell units with and without leukoreduction because the latter was uncommon."

Citations: Alshalani, A., Uhel, F., Cremer, O.L., *et al.* <u>Donor-recipient sex is associated with transfusion-related outcomes in critically ill patients</u>. *Blood Advances*. 2022.

Zhao, J, Sjölander, A., Edgren, G. Mortality among patients undergoing blood transfusion in relation to donor sex and parity. *JAMA Internal Medicine*. 2022.



The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2022 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

#### America's Blood Centers

Chief Executive Officer: Kate Fry Chief Medical Officer: Rita Reik Editor: Mack Benton Subscriptions Manager: Leslie Maundy Annual Subscription Rate: \$390

Send subscription queries to <u>memberservices@americasblood.org</u> America's Blood Centers 1717 K St. NW, Suite 900, Washington, DC 20006 Phone: (202) 393-5725 Send news tips to <u>newsletter@americasblood.org</u>.



#### WORD IN WASHINGTON

**ABC** Newsletter

Rep. Norma Torres (D-Calif.) and Rep. Brian Higgins (D-N.Y.) sent letters to the U.S. Food and Drug Administration (FDA) addressing the deferral of men who have sex with other men (MSM). In her letter, Rep. Torres urged FDA Commissioner Robert Califf, MD to have the agency "[m]ove expeditiously to review the Assessing Donor Variability and New Concepts in Eligibility (ADVANCE) Study and update blood donation guidelines...and work with blood centers to implement the updated guidelines without delay." She also asked the agency to "create a national taskforce to review the U.S. blood supply," per a 2020 report to Congress on the adequacy of the national blood supply, and "requested report language to create a national taskforce to review the blood supply in the Fiscal Year 2023 Agriculture Appropriations bill." Rep. Higgins' letter to Commissioner Califf stated, "[i]t is widely acknowledged in the scientific and medical communities [that] eligibility for blood donation should be based on individual risk and that determining eligibility solely on sexual orientation and gender identity is not a necessary safety measure when considering the risk of blood-based diseases such as HIV/AIDS. In addition to risk assessment measures, FDA-qualified blood donation centers are required to screen donated blood for blood-borne diseases. As part of implementing the recently lifted ban, Canada will instate a new donor screening approach. In addition to Canada, seven other nations recently lift[ed] blood donation restrictions on gay and bisexual men including the United Kingdom, Greece, France, Israel, Hungary, Denmark, and Brazil. It is clear that the three-month deferral requirement is not only unnecessary, but hurtful to willing donors turned away only for their sexual orientation and harmful for the millions of Americans in need of blood transfusions during this shortage."

(Sources: Rep. Norma Torres News Release, 6/14/22; Rep. Brian Higgins News Release, 6/14/22)

The U.S. Department of Health and Human Services' (HHS) Tick-Borne Disease Working Group (TBDWG) has announced its next meeting will take place July 19-20<sup>th</sup>. The purpose of the meeting is to "review the first draft of chapters for the report [to Congress and the HHS Secretary] and further discuss plans for developing the next report to the HHS Secretary and Congress on federal tick-borne activities and research, taking into consideration the 2018 and 2020 report. The 2022 report will address a wide range of topics related to tick-borne diseases, such as, surveillance, prevention, diagnosis, diagnostics, and treatment; identify advances made in research, as well as overlap and gaps in tick-borne disease research; and provide recommendations regarding any appropriate changes or improvements to such activities and research." More information on the meeting is forthcoming including an official notice to be published in the *Federal Register*.

#### Upcoming ABC Webinars – Don't Miss Out!

- ABC Human Resources Forum Webinar June 28<sup>th</sup> from 2-3 PM EDT. More information coming soon.
- The Clinical Laboratory Workforce: Understanding the Challenges to Meeting Current and Future Need-ASCP Blueprint Webinar July 20<sup>th</sup> from 3-4 PM EDT. More information coming soon.
- ABC SMT Journal Club Webinar August 10<sup>th</sup> from 3-4 PM EDT. More information coming soon.
- ABC HIPAA & Privacy in Blood Banking Webinar September 13 from 3-4 PM EDT. More information coming soon.
- ABC Cybersecurity Threats & Mitigation for Blood Centers Webinar September 20 from 3-4 PM EDT. More information coming soon.



**ABC** Newsletter

**RESEARCH IN BRIEF** 

British Society for Haematology Updates Guidelines for Management of Major Hemorrhage. Updated guidelines for the management of major hemorrhage have been published by the British Society for Haematology (BSH). "A total of 96 citations were included." The general recommendations are: "hospitals must have local massive hemorrhage protocols (MHPs) in relevant clinical areas that includes a clear mechanism for contacting all relevant team members and support staff; clinical staff involved in frontline care must be trained to recognize major blood loss early, be familiar with the contents of MHPs and know when to activate and deactivate the MHP; hospitals must have a strategy to ensure that emergency 'universal' red blood cells (RBCs) are readily available for treatment of life-threatening bleeding; group O RhD-and Knegative RBCs should be prioritized for females of childbearing potential." The guidelines also "recommend a standard threshold and target hemoglobin (Hb) range for RBC transfusion alongside clinical judgement on the severity of bleeding (threshold Hb 70g/l)...If major bleeding is on-going and results of standard coagulation tests or near-patient tests are not available, we suggest fresh frozen plasma (FFP) be transfused in at least a 1:2 ratio with RBCs...If major bleeding is on-going, and laboratory results are available, we suggest further FFP be administered aiming to maintain the PT ratio at <1.5-times mean normal." The guidelines also advise "that serial hemostatic tests should be checked every 30–60 minutes to guide and ensure the appropriate use of hemostatic blood components...We suggest fibrinogen supplementation should be given if concentrations fall below 1.5 g/l...If major bleeding is on-going, [use] platelet transfusions to maintain platelet counts at  $>50 \times 109/1$ ... We suggest that viscoelastic hemostatic assays are used to guide transfusion therapy in cardiac surgery." There are additional recommendations for specific settings published in the guidelines including PPH, alternates to transfusion, gastrointestinal bleeding, trauma and surgical bleeding." The article concludes with good practice statements that include an annual review of MHP with regular drills, implementation of "robust patient sample identification systems," and that "hospital transfusion laboratories should have formal training and competency process evaluation, covering all aspects of blood component provision for major hemorrhage cases."

**Citation**: Stanworth, S.J., Dowling, K., Curry, N., Doughty, H., Hunt, B.J., Fraser, L., *et al.*, on behalf of The Transfusion Task Force of the British Society for Haematology. <u>A guideline for the haematological</u> management of major haemorrhage: A British Society for Haematology Guideline. *Br J Haematol*. 2022.

Contributed by Richard Gammon, MD, Medical Director at OneBlood •

#### **BRIEFLY NOTED**

The Sickle Cell Disease Coalition (SCDC) is celebrating World Sickle Cell Awareness Day this year by honoring Dr. Alex Kumar, a global health physician and photojournalist amplifying stories of global warriors' experiences and inspiring resiliency living with sickle cell. The coalition has created assets including a social media toolkit ahead of World Sickle Cell Awareness Day on June 19<sup>th</sup> and is encouraging individuals and organizations to use the tool kit to "to share untold global SCD stories, images, and sample tweets to raise awareness of the disease."

(Source: Sickle Cell Disease Coalition <u>Toolkit</u>, 6/14/22)

#### **ABC Calendar of Events**

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The <u>calendar of events</u> includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



## America's Blood Centers<sup>\*</sup> It's About *Life*. INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

#### ABC Participates in Inaugural Patients' International Blood Alliance Meeting

America's Blood Center's (ABC) Chief Executive Officer Kate Fry, MBA, CAE took part in the Thalassemia International Federation's <u>1<sup>st</sup> Patients' International Blood Alliance (PIBA) Meeting</u> on June 14<sup>th</sup>. Ms. Fry delivered remarks to the audience and participated in a roundtable discussion presenting the perspective of blood establishments on the value of voluntary blood donation. The PIBA Meeting included patient advocates, specialists in hemoglobinopathies, blood donors, professional societies, and blood establishments. The meeting addressed:

- timely concerns regarding blood transfusion therapy;
- ways to improve and support blood safety and availability; and
- the value of voluntary blood donation.

ABC Newsletter

In her comments, Ms. Fry explained, "ABC and our member blood centers promote the altruistic gift of blood nationwide. Our member centers are unique in that they are of their community, for their community. Many of their donors build long-lasting relationship with staff members though years of donating at these particular centers...The blood community will need partners, including patient organizations... I don't have to tell any members of the Patients International Blood Alliance about the importance of this work. Many of its members confront the chronic conditions that require regular blood transfusions. Instead, I want you to know you have a partner in this important work." ABC is also represented on PIBA's Advisory Board.

#### Webinar Recording and Slides Available: U.S.-Wide Red Blood Cell Antibody Exchange Project

A recording and slides of the May 10<sup>th</sup> ABC webinar on the "U.S.- Wide Red Blood Cell Antibody Exchange Project" are now available to ABC members. The webinar featured Jeanne Hendrickson, MD, medical director of the Apheresis Service and associate medical director of the Transfusion Medicine Service at Yale New Haven Hospital, providing background information and a status update on the project and its future direction. This project focuses on antibody exchange at the hospital level. ABC members can find the recording and slides in MCN 22-051. Contact <u>us</u> to receive a copy of the MCN.

#### **Registration Opens for MD Workshop and Summer Summit**

America's Blood Centers (ABC) launched <u>registration</u> for the <u>ABC Medical Directors Workshop and ABC</u> <u>Summer Summit</u> taking place August 2-4 in Minneapolis, Minn. A <u>preliminary program</u> is now available. Over the course of two days, attendees will hear case study rounds, engaging discussions, and have many networking opportunities to connect with peers and colleagues. <u>Hotel reservations</u> can be made now through the ABC block.

-5-



#### **MEMBER NEWS**



LifeStream Director of Community Development Dan Ballister (left), Assembly Majority Leader Eloise Gomez Reyes (center), and LifeStream President/CEO & Medical Director Dr. Rick Axelrod (right)

LifeStream Blood Bank has been selected as a 2022 California Nonprofit of the Year by California Assembly Majority Leader Eloise Gomez Reves. The distinction makes LifeStream one of more than 100 nonprofits honored by their state senators and assemblymembers "for their outstanding contributions to the community." LifeStream President, Chief Executive Officer (CEO), and Medical Director Rick Axelrod, MD, PhD added in the announcement, "[w]e are honored to be among the wonderful nonprofits across California working to better our communities. It is through the support of legislators like Assemblymember Reyes, who care about the health of their community, that enables nonprofits like LifeStream to bring hope and lifesaving services to people in need." Jan Masaoka, CEO of the California Association of Nonprofits (CalNonprofits) which serves as a partner for this awards program, added, "Nonprofit organizations play such a critical role in our communities, and the last two years of the pandemic have only served to highlight that. California Nonprofit of the Year gives elected officials the opportunity to shine a light on the important work nonprofits are doing in their districts and for everyone to appreciate the collective impact of nonprofits in our communities."

(Source: LifeStream Blood Bank Announcement, 6/10/22)

**LifeShare Blood Center** recently celebrated its 80<sup>th</sup> anniversary on June 15<sup>th</sup> with Shreveport, La. Mayor declaring it "LifeShare Blood Center Day," and encouraged eligible individuals to become blood donors. "Becoming a blood donor is a great way for citizens to become involved in their community, while also provid-

Lifeshare BLOOD CENTER We connect donors and the lives they impact!

ing live-saving gifts to the neediest among us" According to a blood center news release, LifeShare was founded in 1942 and is state's oldest blood center and second oldest in the nation. In that time, LifeShare has helped save more than 5 million lives, with over 8 million blood donors having given over 500,000 gallons of whole blood and 642,000 platelets." LifeShare Executive Director of Blood Operation Benjamin Prijatel added in the news release, "LifeShare is honored to have served our communities for over 80 years, and we are especially thankful for each and every blood donor who has supported our mission by unselfishly answering the call to roll up their sleeve."

(LifeShare Blood Center News Release, 6/15/22) •

#### **COMPANY NEWS**

The U.S. Food and Drug Administration's (FDA) Cellular Tissue, and Gene Therapies Advisory Committee (CTGTAC) recommended **bluebird bio's** investigational gene therapy for the treatment of beta thalassemia in individuals who require regular red blood cell (RBC) transfusions. The recommendation was based on data from a biologics license application (BLA), which is currently under priority review with the FDA, with a decision expected by August 19<sup>th</sup>, according to a company news release. Andrew Obenshain, chief executive officer at bluebird bio, stated in the news release, "[d]espite advances in care, people living with the most severe form of beta-thalassemia still require frequent transfusions of healthy red blood cells to survive, tethering them to the healthcare system for life and increasing their risk for severe complications



<u>COMPANY NEWS</u> (continued from page 6)

and early death. Today's advisory committee recommendation is recognition of the substantial body of clinical data that support beti-cel as a potentially curative treatment option for these patients. We are grateful to the members of the beta-thalassemia community who contributed to today's discussion and remain committed to working with the FDA as it completes its review of the beti-cel Biologics License Application."

(Source: bluebird bio <u>News Release</u>, 6/10/22)

**Sysmex America, Inc.** <u>received</u> FDA clearance on June 15<sup>th</sup> for the "addition of residual white blood cell counting to its XN-10 Automated Hematology Analyzer with Blood Bank mode." According to a company news release, "[t]his is the first and only automated hematology analyzer to be FDA-cleared for residual WBC counting. The latest analyzer supports red blood cell (RBC) and platelet (PLT) component testing along with residual white blood cell counting in a single sample aspiration, providing blood processing centers with increased efficiency, consistency and accuracy."

(Source: Sysmex America, Inc. <u>News Release</u>, 6/15/22) •

#### CALENDAR

*Note to subscribers:* Submissions for a free listing in this calendar (published weekly) are welcome. Send information to <u>newsletter@americasblood.org</u>. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

#### 2022

June. 29-30. FDA CTGTAC Meeting (Virtual). More information available here.

July 19-20. U.S. Department of Health and Human Services (HHS) Tick-Borne Disease Working Group Meeting, Washington, D.C. More information available <u>here</u>.

Aug. 2-4. **ABC Summer Summit and Medical Directors Workshop**, **Minneapolis**, **Minn.** Registration is <u>open</u>. More information available <u>here</u>.

Aug. 29-30. National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and the Office of the of the Assistant Secretary of Health (OASH) of the Department of Health and Human Services (HHS) 2022 State of the Science in Transfusion Medicine Workshop (Virtual). More information coming soon.

Sept. 19-22. American Association of Tissue Banks Annual Meeting, San Antonio, Texas. More information available <u>here</u>.

Sept. 21-22. 28<sup>th</sup> IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Porto, Portugal. Registration is <u>open</u>. More information available <u>here</u>.

Sept. 28-29. 2022 ADRP Master Class (Virtual). More information coming soon.

Sept. 28-29. BEST Meeting LXIV, Cocoa Beach, Fla. More information available here.

Oct. 1-4. Association for the Advancement of Blood & Biotherapies Annual Meeting, Orlando, Fla. Registration is <u>open</u>. More information available <u>here</u>.

#### 2023

Mar. 6-8. ABC Annual Meeting, Washington, D.C. More information coming soon.

May 9-11. 2023 ADRP Conference. More information coming soon.

#### **CLASSIFIED ADVERTISING**

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: <u>newsletter@americasblood.org</u>

#### **EQUIPMENT AVAILABLE:**

**For Sale.** New and Unused CompoMat G5 Units. The Blood Bank of Alaska has three new and unused CompoMat G5 Units for sale. These units have not been validated or used. If interested, please contact Bryan Baynard at <u>bbaynard@bbak.org</u> or (907) 222-5664.

#### POSITIONS

Chief Administrative Officer (Shreveport, LA). LifeShare Blood Center is seeking an experienced human resources, risk management, or business administration professional as our Chief Administrative Officer (CAO). Reporting to the President & CEO, the CAO develops and administers Company-wide policies and practices to facilitate business operations and manage risk exposures; ensures compliance with applicable laws, standards and regulations governing various areas of responsibility; and provides executive leadership of human resources, safety, quality assurance, and information systems and technology functions. Please join us in our important mission to connect blood donors and the lives they impact! LifeShare offers a competitive beginning salary, commensurate with experience and a generous benefits package, including employer-paid medical, life and disability insurance; employer base retirement and matching contributions (6%) to the 401(k) savings plan, paid time off bank, and employee wellness program. Visit our Careers Page to apply.

Regional Operations Director (Baton Rouge, LA). LifeShare Blood Center is seeking an Operations Director to oversee blood collection and donor recruitment operations in the Baton Rouge, LA region. Relocation assistance may be available for the right candidate. The Operations Director will develop and implement strategic and tactical plans for donor recruitment and collections within the donor center and community-based activities; direct, develop and coach teams for achievement of established goals and KPI's; develop relationships with community leaders and groups to promote our mission and business needs; ensure operations adhere to standards and regulations governing the blood banking industry; and model LifeShare's mission and values, integrating them into daily decisions, behaviors and actions. Join us in our important mission to connect blood donors and the lives they impact! LifeShare offers a competitive salary, commensurate with experience plus incentive bonus opportunities, as well as a generous benefits package, including employer-paid medical, life and disability insurance; 401k with employer contributions (6%), paid time off bank, and employee wellness program. Visit our Careers Page to apply.

Clinical Laboratory Scientist Specialist. Ranked No. 5 in the nation by U.S. News & World Report, Children's Hospital Los Angeles (CHLA) provides the best care in California. Here world-class experts in medicine, education, and research work together to deliver family centered care half a million times each year. Position Summary: The CLS Specialist functions as a licensed staff member performing duties approved by California Business and Professions Code, CLIA, and other regulatory agencies. Plan, coordinate, and lead all areas of Transfusion Medicine (TM) in activities related to quality and regulatory affairs. Review of all SOPs. Review of all validation plans. Review of all quality audits and other required assessments. Management of the overall deviation management program. Oversee the implementation and the interpretation of the effects of all new and revised standards and guidelines from regulatory and accrediting agencies on TM operations. Serve as the primary contact and liaison with all external regulatory and accrediting agencies. Maintain all licenses, registrations, and certifications required for TM. Education/Licensure: Bachelor's degree in Biology or related science required. Valid California CLS license required. SBB preferred. Minimum Qualifications: Five plus years of relevant experience. Prior experience performing quality functions and working with regulatory and accrediting agencies preferred. AABB assessor preferred. Please click here to view the full job description and apply.

**Director of Quality.** National Blood Testing Cooperative is now interviewing for a Director of Quality who through direct or delegated oversight, ensures financial feasibility, customer, and employee desirability of business decisions, strategic planning, development and execution of all quality systems for the Donor Testing Lab. Creates and fosters a collaborative environment in the organization that allows all employees to work together to further the mission and vision of the organization to ensure that the organization is increasing customer value, growing in a smart and efficient manner driving operational efficiency, inspiring the talent base,



#### **<u>POSITIONS</u>** (continued from page 8)

and continually reinventing the business. A BA in Life Science, nursing, or allied science discipline. Medical Technology (MT), Medical Laboratory Specialist (MLS), or at a minimum, Medical Lab Technology (MLT) certification preferred. Valid driver's license required. A minimum of two to four years Management/Supervisory experience with emphasis on employee development, performance evaluations, coaching and counseling and daily work management. Experience/involvement in strategic planning and execution. Minimum four to six years of Quality Assurance/Quality Management experience with emphasis on quality assurance, process design, error management, document control, auditing, licensure, and ensuring compliance. If you meet the above qualifications, please apply by sending your resume to: wendy@nationalbloodcollaborative.org. EOE/AAE

**QRA Supervisor.** Responsibilities: Quality Assurance/Training/ GMP/GTP/GLP: Lead the department's quality activities, initiatives, and process improvement activities. Perform training on QRA core functions and activities, Good Manufacturing Practice/Good Tissue Practice/Good Laboratory Practice, and safety. Compliance: Ensure compliance to current regulations and accreditation requirements by federal, state, county, and accreditation agencies. Team Leadership: Manage the performance of direct reports. Set team objectives, priorities, and resources to align staff with Blood Center objectives. Safety: Lead the safety, emergency, and disaster management of the organization. Quality Management System: Provide oversight on the appropriate use of the quality management tools in handling the various documents, records, and activities of the blood center. Registration and Licensure: Ensure all licenses, permits and certificates are current and regulatory requirements are met. Qualifications: Bachelor's degree required. One to two plus years supervisory experience in a regulated or GMP (Good Manufacturing Practice) required. Please click here to view the full job description and apply.

Medical Technologist – Overnight/Shift Differential. LifeSouth Community Blood Centers is currently seeking a skilled individual for a Medical Technologist position in our Immunohematology Reference Laboratory (IRL) in Jacksonville, FL. This position is responsible for performing and interpreting clinical laboratory tests that require the exercise of independent judgment. We are looking to fill an overnight/third shift. Starting salary range is \$27.00 - \$32.40 an hour. Shift differential of 15 percent – 20 percent may apply for working overnight hours. Applicants should apply here.

**Director of Finance.** LifeSouth Community Blood Centers is currently seeking an individual to join our team as the Director of Finance in Gainesville, FL. This position



is charged with ensuring the stability of LifeSouth's finances through planning, directing, and controlling financial functions, including establishing appropriate control environments, financial reports for management on the company's financial status, preparing financial reports and analysis, and overseeing the development and implementation of effective financial and accounting systems. The selected candidate will also manage the Purchasing and Accounting departments. Applicants should apply <u>here</u>.

QA Specialist (R2216359) (Stanford Blood Center). Responsibilities: Cover the quality essentials and perform regulated tasks addressing organization, resources, equipment, supplier & customer issues, process control, document and records, deviations and adverse events, assessments, process improvement, and facility & safety. Assist in training appropriate personnel pertaining to QRA and safety activities. Ensure compliance to current regulations, accreditation standards, guidance documents and policies and procedures consistent with the latest releases of Code of Federal Regulations, California Code of Regulations, Health & Safety Codes, Business and Professions Code, AABB Blood Bank and Transfusion Services and College of American Pathologist accreditation standards including local Bills (Assembly and Senate Bills) and applicable County Directives. Perform regulated document reviews of standard operating procedures, forms, training plans, other pertinent documents, change controls, and validations. Also, review and monitor incident and deviation management through the different Quality Management System applications. Act as member of the safety committee member and perform designated roles as Emergency Response Team (ERT), Assembly Point Coordinator (APC). Facilitate external inspection conducted by inspectors. Qualifications: Bachelor's degree required. Three plus years to five years in blood banking, laboratory, or manufacturing with solid familiarity of GMP, safety in a manufacturing setup, and CAL-OSHA regulations required. Please click here to view the full job description and apply.

Manager, Component Manufacturing. LifeStream Blood Bank is seeking a Manager of Component Manufacturing. This role is responsible for the daily leadership and oversight of all manufacturing, labeling storage, and release of blood components, derivatives, and resale products. Establishes proper weekly production schedules to best meet local demand based on current inventory levels and hospital usage. Ensures operations in manufacturing are in compliance with all applicable Federal, State, AABB, OSHA and CLIA guidelines. Oversees the daily and monthly quality control program to ensure products and components are in compliance with established requirements. Responsible for the proper labeling and release of all components based on established Standard Operating Procedures. Ensures team members

#### POSITIONS (continued from page 9)

provide the highest level of customer service to internal and external customers. Education: Four-year bachelor's degree (BA or BS) or equivalent. Experience: Three years laboratory experience in either Blood Banking or a Hospital. Management and/or Supervisory experience preferred. Please click <u>here</u> to view the full job description and apply.

